Prerpints.org logo
Preprint
Review

Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibody for Multiple Sclerosis

Altmetrics

Downloads

147

Views

58

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

22 July 2024

Posted:

22 July 2024

You are already at the latest version

Alerts
Abstract
Background: over the past 20 years, the treatment scenario of multiple sclerosis (MS) has radically changed and an ever-increasing number of disease-modifying treatments has emerged. Among high efficacy treatment agents, monoclonal antibodies (mAbs) have become a mainstay in the MS patient’s treatment due to their targeted mechanism, high efficacy and favorable risk profile. The latter varies from drug to drug and a skin cancer warning has emerged with sphingosine 1-phosphate receptors inhibitors. Several cases of skin malignancy in people with MS (pwMS) undergoing therapy with mAbs have also been described, but dermatological follow-up is not currently indicated. Objectives: the aim of this review is to investigate cases of cutaneous ma-lignancy during mAbs therapy and to explore possible pathophysiological mechanisms to evaluate the potential need for regular dermatological follow-up in pwMS treated with mAbs. Methods: literature search for original articles and review in PubMed. No date restrictions. Results: 1019 results were retrieved. Duplicates were removed using Endnote and manually. Only peer-reviewed studies published in English were considered for inclusion. At the end of these screening procedures, 54 studies published between 2001 and 2023 that met the objectives of this review were selected and reported. Conclusions: the available data do not show a clear link be-tween monoclonal antibody (mAb) treatment in pwMS and the risk of skin cancer. At present, these treatments remain contraindicated for people with cancer. Dermatological screening is ad-visable before starting mAb treatment in pwMS, and subsequent follow-up should be individual-ised according to each patient's risk profile.
Keywords: 
Subject: Medicine and Pharmacology  -   Neuroscience and Neurology

1. Introduction

Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS) and a leading cause of non-traumatic neurological disability in young adults [1].
In the past 20 years, the treatment scenario of MS has radically changed and an ever-increasing number of disease-modifying treatments (DMTs) has emerged, enabling effective reduction of disease activity, disability accrual, and accumulation of irreversible damage by interfering with a variety of immunological mechanisms [2].
DMTs can be classified into drugs of low or moderate-efficacy agents (interferons, glatiramer acetate, teriflunomide, dimethyl fumarate) and high-efficacy treatment agents (HETA) that encomprise S1P modulators, cladribine and monoclonal antibodies (mAbs) [3]. Treatment allocation is driven by an individualized evaluation of the risk–benefit profile, according to disease activity, disease phenotype and patient’s needs. mAbs have become a mainstay in the MS patient’s treatment due to their targeted mechanism, high efficacy and favorable risk profile [2].
mAbs can be classified according to their molecular structure: the first generation of therapeutic mAbs was developed from non-human species such as mice (fully murine). To reduce the potential immunogenicity of murine mAbs, chimeric mouse-human, humanized mAbs and then fully human mAbs were implemented [4].
The first mAb introduced for the MS treatment was Natalizumab (NTZ), an antibody against the α4 subunit of the human integrins, which inhibits the transmigration of lymphocytes across the blood–brain barrier. In contrast, Alemtuzumab (ALZ) and the class of anti-CD20 mAbs (such as Ocrelizumab and Ofatumumab) act as depletors of a specific class of blood cells [2].
The safety profile of HETA varies from drug to drug. In particular, a warning for cutaneous cancers emerged with Fingolimod, a sphingosine 1-phosphate (S1P) receptors inhibitor, that sequesters lymphocytes in lymph nodes and secondary lymphoid tissues. In detail, although the most common cutaneous malignancies in people with MS (pwMS) treated with Fingolimod are basal-cell carcinoma and Bowen disease [5], cases of melanoma have also been reported [6]. These data highlighted the importance of dermatological screening and monitoring in pwMS treated with Fingolimod. Several cases of skin malignancy have also been described in pwMS undergoing therapy with mAbs, but dermatological follow-up is not currently indicated. The aim of this review is to investigate cases of cutaneous malignancies during therapy with mAbs and to explore possible pathophysiological mechanisms to potentially establish the need for regular dermatological follow-up in pwMS treated with mAbs.

2. Materials and Methods

The literature search was conducted using PubMed as electronic database. Studies were identified using a combination of the following Medical Subject Headings (Mesh) terms: “Multiple Sclerosis”; “Melanoma”; “Basal-cell carcinoma”; “Squamous cell carcinoma”; “Skin cancer”; “Skin neoplasm”; “Skin tumor”; “Cancer risk”, “Skin malignancy”; “Highly effective DMT”; “Safety”; “monoclonal antibodies”; “Natalizumab”; “Ocrelizumab”; “Ofatumumab”; “Alemtuzumab”. No date restrictions were used. The reference list was crafted by assessing its pertinence to the themes addressed in this review.

3. Results

A total of 1019 results were retrieved. Duplicates were removed using Endnote (online version) and manually. All articles that did not match the title profile were discarded. Only peer-reviewed studies published in English were considered for inclusion. At the end of these screening procedures, 54 studies published between 2001 and 2023 that met the objectives of this review were selected and reported. Specifically, only articles that addressed safety issues related to mAbs used in the treatment of MS, with a focus on dermatological neoplastic complications, were included.

3.1. Natalizumab

NTZ is a humanized mAb (IgG4k) that targets the α4 subunit of the human integrins (α4/β1 integrin- CD49d/CD29- very late antigen-4 VLA-4), adhesion molecules that are expressed at high levels on the membrane of all leukocytes except neutrophils [7]. NTZ blocks α4β1 integrin interaction with VCAM-1 (or CD106), a vascular cell adhesion molecule, and inhibits leukocyte transmigration across the blood-brain barrier, thereby reducing inflammation in the CNS. NTZ may also exert its anti-inflammatory effects by blocking leukocytes binding to other endothelial components, such as fibronectin and osteopontin, which modulate the survival, priming and activation of white blood cells that have gained access to the CNS parenchyma [8]. In addition, by binding to the α4/β 7 integrin, NTZ prevents its interaction with the endothelial cell adhesion molecule receptor (MadCAM-1). Therefore, in pwMS, anti-VLA-4 treatment reduces the lymphocyte count in cerebrospinal fluid and the relapse rate [9].
NTZ efficacy and safety in patients with relapsing-remitting (RR) MS has been evaluated in a two-year phase 3 clinical trial, the “Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis” (AFFIRM) study [10].
From data sheet the most common adverse events associated with anti-VLA-4 treatment include headache (32%), nasopharyngitis (27%), fatigue (23%), urinary tract infection (16%), nausea (15%), arthralgia (14%), and dizziness (11%) [11].
Progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus, is a less common but frightening complication that can be fatal or severely disabling [12].
In the AFFIRM trial, five cases of cancer were reported in the group of pwMS treated with NTZ (three cases of breast cancer, one case of stage 0 cervical cancer, and one case of newly diagnosed metastatic melanoma) [10].
The long-term safety and efficacy of NTZ in RRMS patients has been evaluated in the Tysabri Observational Program (TOP), an open-label, multinational, prospective, observational study, including data from July 2007 to November 2017 [13]. Notably, the rates of development of malignancies remained very low: 66 out of 6148 enrolled pwMS (1.1%), with 39 different types of malignancy. The most common malignancy was breast cancer (in 19 pwMS). The dermatological malignancies detected in the study were: melanoma in situ (2 cases), choroidal melanoma (1 case), basal cell carcinoma (1 case), lentigo maligna (1 case).
The Southern Network on Adverse Reactions (SONAR), a National Cancer Institute-funded pharmacovigilance program, found an association between NTZ treatment and the risk of melanoma [14]. Data sources included adverse events reported at Food and Drug Administration (FDA) and peer-reviewed publications. In particular, the FDA Adverse Event Reporting System (FAERS) described 137 reports of NTZ-associated melanoma. The median age at diagnosis of melanoma was 45 years. 16% developed from pre-existing nevi. In 34% of pwMS, melanoma was diagnosed within 2 years of NTZ start.
Analysing data from the FAERS, EudraVigilance (European Medicines Agency), and the Northwestern Medicine Enterprise Data Warehouse (NMEDW), the Research on Adverse Drug events And Reports (RADAR) program confirmed SONAR findings [15].
Conversely, Castela et al. showed no increased rate of clinical and dermoscopic changes of 248 pigmented lesions in 44 pwMS treated with NTZ during a prospective follow-up of 14 months [16]. Pharaon et al. confirmed this finding in 74 pwMS with 775 melanocytic skin lesions monitored up for more than 4 years. No melanoma was diagnosed. In addition, in vitro analysis of moles removed during follow-up of NTZ-treated MS patients, showed reduced expression of secreted acidic cysteine-rich protein (SPARC) and β3 integrin on melanocytic cells, proteins that are normally able to promote melanoma invasiveness. Furthermore, a combined in vitro approach was performed to analyse the effects of NTZ on cultured melanoma cells, which demonstrated anti-invasive and anti-migratory properties of the drug in a dose-dependent manner [17].
Alping et al. evaluated the risk of cancer in 6,136 pwMS treated with rituximab, NTZ, and Fingolimod, compared with 37,801 subjects from the non-MS general population. Of 1670 pwMS treated with NTZ only 2 developed melanoma and no case of other skin cancer was reported [18].
“Tysabri global observational program in safety” (TYGRIS) study evaluated the risk of cancer during 5 years of follow-up in 6434 enrolled pwMS who received at least one dose of NTZ [19]. Basal cell carcinoma was reported in 10 pwMS and melanoma in 13, excluding one case of metastatic melanoma without an identified primary site on the skin. Melanoma in situ was present in 5 of these cases. Overall when these results were compared with the Surveillance, Epidemiology and End Results (SEER) (for US general population) and with GLOBOCAN (for European general population) rates, there was no evidence of an increased risk of melanoma in pwMS treated with NTZ.

3.2. Ocrelizumab

OCR is an intravenously administered, humanized anti-CD20 mAb, that depletes B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and apoptosis, while sparing the capacity for B cell reconstitution, pre-existing humoral immunity and innate immunity [20].
The efficacy and safety of OCR has been evaluated in three pivotal phase 3 trials named OPERA I and OPERA II (for pw RR-MS) and ORATORIO (for patients with primary-progressive (PP- MS) [21,22].
In particular, the OCR groups were made up of 410 pwMS in OPERA I trial, and 417 pwMS in OPERA II trial. Over the 96-week study period, one of the four malignancies reported in the two OCR groups was malignant melanoma. Five additional neoplasms were reported during the open-label extension phase, two of which were basal cell skin cancer and one malignant melanoma [21].
In the ORATORIO study, of the 11 neoplasms detected in the 486 pwMS enrolled in the OCR arm, 3 were basal cell carcinomas. Two additional cases of neoplasia were reported during the open-label extension phase: one case of basal cell carcinoma and one case of squamous cell carcinoma [22].
According to European Public Assessment Reports (EPAR), OCR may increase the risk of malignancies (e.g., breast cancer) and its use is therefore contraindicated in patients with known malignancies in the European Union [23].
In a single-arm, open-label, phase 3 trial, CASTING, only one case of basal cell carcinoma was detected among 680 pwMS treated with OCR [24].
Nevertheless, safety analyses based on integrated clinical and laboratory data from all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials (VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO) suggest long-term tolerability and no increased risk of malignancy or female breast cancer compared with matched reference MS and general populations or a time-dependent exposure effect [25]. Specifically, the standardized rate of non-melanoma skin cancer (0.20 per 100 patient-years [PY] of exposure [95% CI 0.11–0.38]) remained constant and in line with epidemiological benchmarks (0.19 per 100 PY [95% CI 0.15–0.24]).
Smoot and colleagues conducted a prospective cohort study of 355 MS patients treated with OCR from the Providence Ocrelizumab Registry. Of these patients, 32 (9%) had a history of cancer, and eight patients were subsequently diagnosed with cancer after starting OCR: four with basal cell carcinoma, two with breast cancer, one with recurrent thyroid cancer and one with melanoma [26].
These results align with observations with other anti-CD20 treatments such as rituximab, which do not show a propensity for primary malignancies [27]. Ongoing post-approval safety studies (CONFIDENCE, MANUSCRIPT, VERISMO) involving approximately 9,000 pwMS newly treated with OCR aim to provide insights into long-term safety, particularly assessing the potential risk of malignancies [28,29,30]. Weber and colleagues presented data from the two-year interim analysis of the CONFIDENCE study, which included 1702 patients with RMS and 398 patients with PPMS, that have been treated with ≥1 dose of OCR. Ten malignancies were reported. Seven occurred in patients with RMS: two cases of malignant melanoma, one case each of basal cell carcinoma, bronchial carcinoma, and thyroid cancer. Three patients with PMS had neoplasms, all cutaneous: a malignant melanoma, a squamous cell carcinoma of the skin and a basal cell carcinoma [31].
Consistent with previous literature, an international retrospective pharmacovigilance disproportionality analysis performed in the WHO pharmacovigilance database, VigiBase®, from 1 January 2000 to 1 September 2019, found no evidence of an association between OCR and a risk of skin cancer [32,33,34].

3.3. Ofatumumab

OFA is a subcutaneous administered, fully human, anti-C20 mAb, approved for RRMS. OFA binds a small exposed extracellular loop epitope of the CD20 receptor, distinct from that recognized by rituximab and OCR, and depletes B cells via complement-dependent cytotoxicity and, to a lesser extent, antibody-dependent cell-mediated cytotoxicity. For this reason, OFA has higher affinity for B cells and higher potency compared to aforementioned anti-CD20 mAbs and is able to achieve almost complete B-cell depletion at a lower concentration [35]. OFA has been tested in adult RRMS patients in the Phase 3 ASCLEPIOS I and II trials and has shown a favorable benefit-risk profile compared to teriflunomide in the broad RRMS population. In these phase 3 trials five neoplasms (0.5%) occurred in the OFA group, three of which were cutaneous (two basal cell carcinomas and one melanoma) and four (0.4%) in the teriflunomide group (two cases of basal cell carcinoma and one case each of cervical carcinoma and fibrosarcoma) [36]. Preliminary results from the ongoing extension study (ALITHIOS) indicate that RRMS patients undergoing long-term treatment with OFA for up to 4 years show good tolerability, with no new safety concerns detected. The occurrence of malignancies was minimal, as indicated by the overall safety analysis set, with an incidence of 0.86% and an estimated annualized incidence rate (EAIR) of 0.33 (95% CI: 0.20–0.53), similar to that observed during the core period of the ASCLEPIOS I/II OFA arm (incidence of 0.53% and an EAIR of 0.32 (95% CI: 0.13–0.77)) [37].

3.4. Alemtuzumab

ALZ is a humanized IgG mAb that binds the CD52 antigen, a cell surface glycoprotein, expressed by T and B lymphocytes, monocytes, macrophages, eosinophils, natural killer cells, thymocytes and the male reproductive system. ALZ causes cell lysis and depletion of T and B lymphocytes, via complement fixation, antibody-dependent cell-mediated cytotoxicity and induction of apoptosis.
ALZ has its most pronounced impact on cell immunity, leading to profound and extended lymphopenia, primarily affecting CD4+ lymphocytes, although the deficiency is never entirely exclusive. Indeed, ALZ influences B lymphocytes, resulting in a reduction in the count of circulating antibodies [38].
A specific pattern of lymphocyte repopulation and a shift in cytokine expression towards a less inflammatory profile follows cell depletion, leading to a durable efficacy; B-cell and monocyte counts typically normalize within three months. In contrast, T-cell counts are suppressed for a longer period, with an average recovery time of 30 months for CD8+ and 60 months for CD4+ to return to pre-treatment levels. ALZ is used in the treatment of B-cell malignancies, as induction therapy for solid organ transplantation, in advanced cases of mycosis fungoides, and in various hematological disorders. In the European Union, ALZ is authorized for use in adults diagnosed with active RRMS, as defined by clinical or imaging features [38].
The efficacy and safety of ALZ in pwRRMS have been evaluated in three pivotal studies: Phase II (CAMMS223) and Phase III “Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis 1 and 2” (CARE-MS and CARE MS-II). [39,40,41]. In phase 3 clinical trials, ALZ and high-dose s.c. interferon-beta-1a were compared in treatment-naïve RRMS patients (CARE-MS I) and in RRMS patients with breakthrough disease who were receiving platform therapies (CARE-MS II). The most common adverse events observed in clinical trials and post-marketing experience included infusion-associated reactions (IARs, such as pyrexia, chills, rash, urticaria and dyspnea), increased risk of infections and autoimmune disorders such as thyroid disorders, autoimmune thrombocytopenia or other cytopenias (such as neutropenia or pancytopenia) and autoimmune nephropathies. Preliminary data in pwMS do not suggest an association between ALZ and increased incidence of any cancer, including skin cancer. Overall, in all clinical trials, 29 out of 1,486 patients treated with ALZ developed malignancies, including 6 basal cell carcinomas and 4 melanomas. In summary, neoplasms were not statistically more frequent with ALZ than with the comparator interferon-beta-1a [39,40,41]. These findings were confirmed by a registry-based cohort study of the entire Danish MS population receiving ALZ between 2009 and 2019, with a total of 209 enrolled patients [42].
A case of malignant transformation of a melanocytic naevus following treatment with ALZ was reported by A. Pace et al. in 2008 [43]. The patient was a 34-year-old woman with aggressive relapsing MS, previously treated with beta-interferon (stopped two years earlier), who received 120 mg of ALZ divided over five consecutive days, with no immediate side effects apart from a transient cutaneous rash. Six months after treatment she was diagnosed with a superficial spreading melanoma in the vertical growth phase, arising from a long-standing melanocytic naevus on her back. The lesion had a mild lymphocytic infiltrate. Two other cases of melanoma have been reported in a retrospective study of Austrian patients (n = 100) treated with ALZ for B-cell chronic lymphocytic leukemia [44].
Registration extension studies and pharmacovigilance analyses seem to refute the association between ALZ and an increased risk of skin cancer.
Results from an extension study (NCT00930553) in patients who received ALZ during the core CARE-MS showed a total of 6 malignancies over 5 years. Two malignancies occurred in the core study, while 4 malignancies were reported in years 3–5. Of these, only one malignancy affected the skin, specifically keratoacanthoma [45].
The CAMMS03409 and TOPAZ extension studies assessed efficacy and safety of ALZ over 12 years of follow-up; in these extension studies, out of a total of 60 patients, only two developed malignancies: all were melanomas and occurred during the 10th year of follow-up. A patient with a family history of melanoma developed two grade 4 malignant melanomas, which the study investigator deemed possibly related to the study drug. The second patient was diagnosed with grade 2 melanoma in situ on the abdomen, a condition that the investigator considered unrelated to the study drug and was resolved by surgical excision [46,47].
An observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from the World Health Organization database (VigiBase®) and found no association between ALZ and cancer reporting [48].

4. Discussion

This review summarizes the cases of skin malignancy during therapy with mAbs, both during pivotal trials, observational studies and pharmacovigilance open data (Table 1).
Despite the data available in the literature, the debate on a possible association between cutaneous malignancies and MS therapy with mAbs is still open.

4.1. Natalizumab

Among the mAbs used in MS, the largest available data concerns skin malignancies reported in treatment with NTZ. NTZ acts by inhibiting VLA-4, an integrin that plays an important role in melanocyte cell homeostasis. Integrins constitute a large family of heterodimeric transmembrane glycoproteins responsible for mediating cell-cell and cell-environment interactions. Integrins consist of two subunits: the α-subunit, ranging in size from 120 to 170 kDa, and the β-subunit, measuring 90–100 kDa. In humans, there are 18 α-subunits and 8 β-subunits that can combine to form 24 different integrins, each characterized by unique binding properties, tissue distribution, and biological functions. Notably, integrin β1 is the most abundantly expressed integrin subunit. It forms heterodimers with at least 12 α-subunits, giving rise to 12 different isoforms [50].
A member of this family is the very late activation antigen-4 (VLA-4, α4β1), which is expressed under physiological conditions in various leukocyte subtypes. It is also identified on melanoma, osteosarcoma, and rhabdomyosarcoma cells [51].
Several studies suggest that VLA-4 expression on melanoma cells may promote metastatic spread of the tumor: VLA-4 can interact with its ligand, vascular cell adhesion molecule-1 (VCAM-1), which is expressed by activated endothelium. This interaction mediates adhesion and facilitates subsequent transmigration of tumor cells. In contrast to benign melanocytic lesions, malignant melanomas exhibit elevated expression of VLA-4, enabling tumor cells migration through vascular system into any tissue in which endothelial VCAM-1 is expressed. Therefore, the increased expression of VLA-4 on melanoma is correlated with an unfavorable clinical outcome and, if so, inhibition of α4β1 integrin could prevent the spread of metastases [51].
Moreover, there is some evidence that the α4β1 integrin is involved in the lymph node dissemination of melanoma cells [52]. Specifically, α4β1 expressed on tumor cells mediates their binding to lymphatic endothelial cells (LECs) via VCAM-1. In addition, the lymphangiogenic growth factor VEGF-C, secreted by tumor cells and transported in the extracellular matrix, appears to promote the expression and activation of α4β1 integrin on LECs, while inhibition of α4β1 in LECs appears to significantly prevent lymphangiogenesis at the tumor periphery and the formation of lymph node metastases [52]. Many studies have pointed out that tumor lymphangiogenesis plays a role in promoting lymphatic metastases, providing a direct conduit for tumor cells to escape to nearby draining lymph nodes. In addition, overexpression of integrin α4β1 on primary melanoma cells appears to be associated with increased bone metastasis, probably through interaction with VCAM-1, which is constitutively expressed on bone marrow stromal cells [53].
While several studies suggest that VLA-4 expression may promote melanoma metastasis, Qian et al. showed that overexpression of the cell surface integrin α4β1 prevented the invasion of highly metastatic melanoma cells by facilitating homotypic intercellular adhesion, without having a significant effect on tumorigenicity and tumor cell growth [54]. Therefore, there is a concern that an antibody such as NTZ that binds to α4 may influence melanoma cell replication, invasion, and migration at the cellular level. Recent evidence suggests that the effect of NTZ may vary depending on the drug dose and the specific melanoma cell line [49]. In particular, studding in vitro three different human melanoma cell lines (LCP-Mel, GR-Mel and WM115) derived from primary tumors, Carbone et al. found that, regarding GR-Mel and LCP-Mel, cell migration significantly augmented after treatment with NTZ. On the other hand, WM115 cell line had a lower migration rate, upon treatment with NTZ [49]. Furthermore, NTZ could affect melanoma development and progression through different mechanisms, one of these may be interference with innate immunity.
Several studies have demonstrated the significant role of natural killer cells (NK) in the defense against melanoma [55].
NK cells, as effector lymphocytes in the innate immune system, play a crucial role in controlling diverse tumors and microbial infections through a dual mechanism. This involves both cytotoxic functions and the production of cytokines. The activation of NK cells is regulated by an elaborate receptor system, that includes several cell surface activating and inhibitory receptors. This system enables NK cells to differentiate between normal cells expressing MHC class I and diseased cells lacking MHC class I molecules on the surface, a phenomenon observed in neoplastic cells, including melanomas. VLA-4 is expressed on NKs and is involved in their migration across endothelial membranes. The observation that blockade of VLA-4 reduces NK cytotoxicity and modulates crosstalk with melanoma cells suggests that VLA-4 plays a role not only in NK cell adhesion and migration across the endothelial barrier, but also as an activating signal in the key functions of these cells. Moreover, studies have shown that prolonged in vitro treatment of human NK cells expressing integrin α4β1 with inhibitors such as NTZ, led to a decrease in NK cell degranulation as well as a reduced NK cells migration towards melanoma cells. Finally, α4β1 integrin expression was reduced by NTZ treatment both in vitro and in pwMS, and decreased with the duration of NTZ therapy, suggesting that this drug may alter NK-mediated immune surveillance against melanoma with a protumorigenic outcome [55].
Kimura et al. have shown that NTZ, as an α4 antagonist, can act on different types of T lymphocytes expressing this antigen (TH1, TH17, T-reg), but appears to exert its effect primarily on T-reg lymphocytes, reducing their circulating levels and disrupting the balance between inflammatory and regulatory T cells in the CD49d+ population [56].
T-regs play a crucial role in maintaining immune balance and preventing autoimmune reactions, yet they can hinder anti-tumor immune responses, potentially exacerbating cancer progression. Elevated T-reg numbers and a low CD8+ T cell/Treg ratio are often associated with poor prognosis in several cancer types, including melanoma, head and neck squamous cell carcinoma, ovarian cancer, and colorectal carcinoma [57].
The functional importance of T-regs in cancer has been demonstrated in murine models of melanoma, where transient depletion of T-regs leads to enhanced anti-tumor immunity, improved tumor clearance, and prolonged survival. Numerous studies have shown an increased presence of T-regs in the peripheral blood of patients with metastatic melanoma compared to healthy individuals of similar age. In addition, T-regs are highly concentrated within the tumor microenvironment of melanoma patients, including primary lesions, affected lymph nodes, and metastatic sites, where they exert potent immunosuppressive effects [58].
In this context, the anti-Treg action carried out by NTZ, may have beneficial effects in patients with melanomatous skin lesions.

4.2. Anti CD20 mAbs

The limited data available on skin malignancies in patients treated with OCR result from pivotal and open-label trials. These data allow a reflection on the role of CD20 in dermatological neoplastic lesions.
Several studies have reported significant amounts of infiltrating CD20+ cells in melanoma lesions [59,60,61,62,63]. However, although the role of B cells in melanoma has been extensively investigated, the results of studies have been conflicting, resulting in both pro- and anti-tumor functions. Some studies have shown that high percentages of both intratumoral and peritumoral B cell infiltrates correlate positively with both survival and metastasis rate [59,60]. Conversely, other studies found a correlation between poor prognosis and intra-tumoral CD20+ cell infiltration, or no significant correlation between these 2 parameters [62,63]. The conflicting results of some studies could be due to several factors, mainly the different stages of melanoma [64].
Several studies have shown that the tumor-promoting activity of sunlight in the skin is mediated by UV-induced DNA damage, suppression of anti-tumor immune responses and promotion of subcutaneous inflammation. A more recent finding is that UV suppresses immunity in mice by activating a specific subtype of regulatory B cells. Using a murine model of photo-carcinogenesis, L-F Kok et al. showed that the depletion of UV-activated immunoregulatory B cells limits UV-induced skin tumor growth, improves survival and/or prevents metastasis to skin-draining lymph nodes. The researchers investigated the effect of anti-CD20 antibodies compared to placebo in mice exposed to increasing doses of UV radiation, before and after the appearance of UV-induced skin lesions [65]. They showed no prophylactic effect of B-cell depletion before the appearance of skin lesions on UV-induced skin cancer, while treatment of tumour-bearing mice with anti-CD20 antibodies significantly reduced tumor growth and metastasis.
In line with these findings, previous studies have shown that UV-activated B cells suppress T-cell-driven immune responses, in part by interfering with dendritic cells and producing immunoregulatory IL-10 [66]. Kok et al., with their studies, ascertained the therapeutic efficacy of anti-CD20 mAbs in mice with UV-induced skin tumors, raising the possibility of using the same strategy in humans upon demonstration that the results obtained in mice hold true for humans [65].

4.3. Alemtuzumab

While it is known that CD52 expression in chronic lymphocytic leukemia and breast cancer has prognostic and predictive value, its significance in melanoma is unclear [67,68,69]. Little is known about the role of CD52-inhibitors in skin tumors. Luka de Vos-Hillebrand and colleagues investigated the prognostic and predictive significance of CD52 mRNA expression in melanoma, examining its impact on prognosis, response to immune checkpoint blockade (ICB), and elements of the tumor microenvironment (TME) [70]. Their studies showed that CD52 mRNA is expressed in a small subset of melanoma cells that co-express the immune checkpoint and that CD52 expression correlates with specific response characteristics to ICB in melanoma. Therefore, the use of anti-CD52 as an ALZ requires caution in patients receiving concurrent therapy with immune checkpoint inhibitors [70].

5. Conclusions

Although the immune system and its regulation may play a crucial role in the development, progression or metastasis of a skin malignancy, the currently available data do not allow to establish a clear link between treatment with mAbs and the risk of skin cancer. The variability of the results could depend on several factors, beyond the action on a specific target, such as the drug dose and the specific melanoma cell line. Further preclinical, long-term clinical studies as well as pharmacovigilance reports should be encouraged to clarify these aspects. Currently, these therapies remain contraindicated in people with malignancies. Therefore, a dermatological evaluation is advisable before starting mAbs in pwMS. However, the dermatological follow-up program in patients receiving mAbs should be individualized and based on the risk profile of each individual, taking into account, among other factors, age, personal and family history of skin cancer, actinic damage and the presence of other drugs that may increase risk.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Oh, J.; Vidal-Jordana, A.; Montalban, X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018 Dec;31(6):752-759.
  2. Krajnc, N.; Bsteh, G.; Berger, T.; Mares, J.; Hartung, H.P. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics. 2022 Apr;19(3):753-773.
  3. Hartung, HP.; Cree, BAC.; Barnett, M.; Meuth, SG.; Bar-Or, A.; Steinman, L. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis. Front Immunol. 2023 Nov 29;14:1290666.
  4. Voge, NV.; Alvarez, E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019 Mar 14;7(1):20.
  5. Kappos, L.; Radue, EW.; O’Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; Burtin, P.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387-401.
  6. Jiang, M.; Lam, L.; Zhuang, Y.; et al. Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review. Curr Derm Rep 12, 300–313 (2023).
  7. Rudick, R.; Polman, C.; Clifford, D.; Miller, D.; Steinman, L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013 Feb;70(2):172-82.
  8. Khoy, K.; Mariotte, D.; Defer, G.; Petit, G.; Toutirais, O.; Le Mauff, B. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
  9. Stüve, O.; Marra, CM.; Jerome, KR.; Cook, L.; Cravens, PD.; Cepok, S.; Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 May;59(5):743-7.
  10. Polman, CH.; O’Connor, PW.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, DH.; Phillips, JT.; Lublin, FD.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, MA.; Sandrock, AW.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899-910.
  11. Tysabri: EPAR - Medicine overview European Medicines Agency. Available online: https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf.
  12. Hellwig, K. Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol. 2011 Nov;258(11):1920-8.
  13. Butzkueven, H.; Kappos, L.; Wiendl, H.; Trojano, M.; Spelman, T.; Chang, I.; Kasliwal, R.; Jaitly, S.; Campbell, N.; Ho, PR.; Licata, S. Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668.
  14. Sabol, RA.; Noxon, V.; Sartor, O.; Berger, JR.; Qureshi, Z.; Raisch, DW.; Norris, LB.; Yarnold, PR.; Georgantopoulos, P.; Hrushesky, WJ.; Bobolts, L.; Ray, P.; Lebby, A.; Kane, RC.; Bennett, CL. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017 Jul;6(7):1541-1551.
  15. Kelm, RC.; Hagstrom, EL.; Mathieu, RJ.; Orrell, KA.; Serrano, L.; Mueller, KA.; Laumann, AE.; West, DP.; Nardone, B. Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program. J Am Acad Dermatol. 2019 Mar;80(3):820-821.
  16. Castela, E.; Lebrun-Frenay, C.; Laffon, M.; Rocher, F.; Cohen, M.; Leccia, NC.; Bahadoran, P.; Lacour, JP.; Ortonne, JP.; Passeron, T. Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch Dermatol. 2011 Jan;147(1):72-6.
  17. Pharaon, M.; Tichet, M.; Lebrun-Frénay, C.; Tartare-Deckert, S.; Passeron, T. Risk for Nevus Transformation and Melanoma Proliferation and Invasion During Natalizumab Treatment: Four Years of Dermoscopic Follow-up With Immunohistological Studies and Proliferation and Invasion Assays. JAMA Dermatol. 2014;150(8):901–903.
  18. Alping, P.; Askling, J.; Burman, J.; Fink, K.; Fogdell-Hahn, A.; Gunnarsson, M.; Hillert, J.; Langer-Gould, A.; Lycke, J.; Nilsson, P.; Salzer, J.; Svenningsson, A.; Vrethem, M.; Olsson, T.; Piehl, F.; Frisell, T. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 May;87(5):688-699.
  19. Foley, J.; Carrillo-Infante, C.; Smith, J.; Evans, K.; Ho, PR.; Lee, L.; Kasliwal, R.; Stangel, M.; Vermersch, P.; Hutchinson, M.; Marinelli, F.; Smirnakis, K. TYGRIS investigators. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord. 2020 Apr;39:101863.
  20. Lamb, YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022 Feb;82(3):323-334.
  21. Hauser, SL.; Bar-Or, A.; Comi, G.; et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis [supplementary appendix appears online]. N Engl J Med 2017;376:221-234.
  22. Montalban, X.; Hauser, SL.; Kappos, L.; Arnold, DL.; Bar-Or, A.; Comi, G.; et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. (2017) 376:209–20.
  23. Ocrevus: EPAR - Medicine overview European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus.
  24. Vermersch, P.; Oreja-Guevara, C.; Siva, A.; Van Wijmeersch, B.; Wiendl, H.; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Comi, G. CASTING Investigators. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial. Eur J Neurol. 2022 Mar;29(3):790-801.
  25. Hauser, SL.; Kappos, L.; Montalban, X.; Craveiro, L.; Chognot, C.; Hughes, R.; Koendgen, H.; Pasquarelli, N.; Pradhan, A.; Prajapati, K.; Wolinsky, JS. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021 Oct 19;97(16):e1546-e1559.
  26. Smoot, K.; Chen, C.; Stuchiner, T.; et al. Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. BMJ Neurol Open 2021;3:e000108.
  27. Alping, P.; Askling, J.; Burman, J.; Fink, K.; Fogdell-Hahn, A.; Gunnarsson, M.; Hillert, J.; Langer-Gould, A.; Lycke, J.; Nilsson, P.; Salzer, J.; Svenningsson, A.; Vrethem, M.; Olsson, T.; Piehl, F.; Frisell, T. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 May;87(5):688-699.
  28. Dirks, P.; Zingler, V.; Leemhuis, J.; et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. BMC Neurol. 2020 Mar 14;20(1):95.
  29. Hauser, SL.; Kappos, L.; Montalban, X.; Craveiro, L.; Chognot, C.; Hughes, R.; Koendgen, H.; Pasquarelli, N.; Pradhan, A.; Prajapati, K.; Wolinsky, JS. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021 Oct 19;97(16):e1546-e1559.
  30. Wormser, D.; Evershed, J.; Ferreira, G.; et al. VERISMO: a post-marketing safety study to determine the incidence of all malignancies and breast cancer in patients with multiple sclerosis treated with ocrelizumab (P4.2-043). Neurology. 2019;92(15 Supplement):P4.2–.
  31. Weber, MS.; Buttmann, M.; Meuth, SG.; Dirks, P.; Muros-Le Rouzic, E.; Eggebrecht, JC.; Hieke-Schulz, S.; Leemhuis, J.; Ziemssen, T. Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study. Front Neurol. 2022 May 9;13:863105.
  32. Lebrun, C.; Vermersch, P.; Brassat, D.; Defer, G.; Rumbach, L.; Clavelou, P.; et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol. 2011 Jul;258(7):1304–11.
  33. Stamatellos, V.; Siafis, S.; Papazisis, G. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol 2021;87:4769-4779.
  34. Dolladille, C.; Chrétien, B.; Peyro-Saint-Paul, L.; Alexandre, J.; Dejardin, O.; Fedrizzi, S.; Defer, G. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. Neurotherapeutics. 2021 Jul;18(3):1657-1664.
  35. Hauser, SL.; Kappos, L.; Bar-Or, A.; Wiendl, H.; Paling, D.; Williams, M.; Gold, R.; Chan, A.; Milo, R.; Das Gupta, A.; Karlsson, G.; Sullivan, R.; Graham, G.; Merschhemke, M.; Häring, DA.; Vermersch, P. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurol Ther. 2023 Oct;12(5):1491-1515.
  36. Hauser, SL.; Bar-Or, A.; Cohen, JA.; Comi, G.; Correale, J.; Coyle, PK.; Cross, AH.; de Seze, J.; Leppert, D.; Montalban, X.; Selmaj, K.; Wiendl, H.; Kerloeguen, C.; Willi, R.; Li, B.; Kakarieka, A.; Tomic, D.; Goodyear, A.; Pingili, R.; Häring, DA.; Ramanathan, K.; Merschhemke, M.; Kappos, L. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.
  37. Hauser, SL;. Zielman, R.; Das Gupta, A.; Xi, J.; Stoneman, D.; Karlsson, G.; Robertson, D.; Cohen, JA.; Kappos, L. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. Mult Scler. 2023 Oct;29(11-12):1452-1464.
  38. Evan, JR.; Bozkurt, S.; Thomas, NC.; Bagnato, F. Alemtuzumab for the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, (2018), 14712598.2018.1425388–.
  39. CAMMS223 Trial Investigators; Coles, AJ.; Compston, DA.; Selmaj, KW.; Lake, SL.; Moran, S.; Margolin, DH.; Norris, K.; Tandon, PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23;359(17):1786-801.
  40. Cohen, JA.; Coles, AJ.; Arnold, DL.; Confavreux, C.; Fox, EJ.; Hartung, HP.; Havrdova, E.; Selmaj, KW.; Weiner, HL.; Fisher, E.; Brinar, VV.; Giovannoni, G.; Stojanovic, M.; Ertik, BI.; Lake, SL.; Margolin, DH.; Panzara, MA.; Compston, DA. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1819-28.
  41. Coles, AJ.; Twyman, CL.; Arnold, DL.; Cohen, JA.; Confavreux, C.; Fox, EJ.; Hartung, HP.; Havrdova, E.; Selmaj, KW.; Weiner, HL.; Miller, T.; Fisher, E.; Sandbrink, R.; Lake, SL.; Margolin, DH.; Oyuela, P.; Panzara, MA.; Compston, DA. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39.
  42. Theodorsdottir, A.; Debrabant, B.; Magyari, M.; Kant, M.; Rasmussen, PV.; Malmberg, CF.; Norberg, IA.; Hansen, V.; Bech, D.; Schmidt, MF.; Schreiber, K.; Frederiksen, JL.; Sellebjerg, F.; Illes, Z. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Mult Scler. 2021 Dec;27(14):2254-2266.
  43. Pace, AA.; Zajicek, JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol. 2009 Apr;16(4):e70-1.
  44. Fiegl, M.; Falkner, A.; Hopfinger, G.; et al. for the Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukaemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. Cancer 2006; 107: 2408–2416.
  45. Havrdova, E.; Arnold, DL.; Cohen, JA.; Hartung, HP.; Fox, EJ.; Giovannoni, G.; Schippling, S.; Selmaj, KW.; Traboulsee, A.; Compston, DAS.; Margolin, DH.; Thangavelu, K.; Rodriguez, CE.; Jody, D.; Hogan, RJ.; Xenopoulos, P.; Panzara, MA.; Coles, AJ. CARE-MS I and CAMMS03409 Investigators. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. 2017 Sep 12;89(11):1107-1116.
  46. Coles, AJ.; Arnold, DL.; Bass, AD.; Boster, AL.; Compston, DAS.; Fernández, Ó.; Havrdová, EK.; Nakamura, K.; Traboulsee, A.; Ziemssen, T.; Jacobs, A.; Margolin, DH.; Huang, X.; Daizadeh, N.; Chirieac, MC.; Selmaj, KW. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134.
  47. Okai, AF.; Amezcua, L.; Berkovich, RR.; Chinea, AR.; Edwards, KR.; Steingo, B.; Walker, A.; Jacobs, AK.; Daizadeh, N.; Williams, MJ. CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study). Neurol Ther. 2019 Dec;8(2):367-381.
  48. Dolladille, C.; Chrétien, B.; Peyro-Saint-Paul, L.; Alexandre, J.; Dejardin, O.; Fedrizzi, S.; Defer, G. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. Neurotherapeutics. 2021 Jul;18(3):1657-1664.
  49. Carbone, ML.; Lacal, PM.; Messinese, S.; De Giglio, L.; Pozzilli, C.; Persechino, S.; Mazzanti, C.; Failla, CM.; Pagnanelli, G. Multiple Sclerosis Treatment and Melanoma Development. Int J Mol Sci. 2020 Apr 22;21(8):2950.
  50. Huang, R.; Rofstad, EK. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J Exp Clin Cancer Res. 2018 Apr 27;37(1):92.
  51. Schlesinger, M.; Roblek, M.; Ortmann, K.; Naggi, A.; Torri, G.; Borsig, L.; Bendas, G. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Thromb Res. 2014 May;133(5):855-62.
  52. Huang, R.; Rofstad, EK. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J Exp Clin Cancer Res. 2018 Apr 27;37(1):92.
  53. Garmy-Susini, B.; Avraamides, CJ.; Schmid, MC.; Foubert, P.; Ellies, LG.; Barnes, L.; Feral, C.; Papayannopoulou, T.; Lowy, A.; Blair, SL.; Cheresh, D.; Ginsberg, M.; Varner, JA. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010 Apr 15;70(8):3042-51.
  54. Qian, F.; Vaux, DL.; Weissman, IL. Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell. 1994 May 6;77(3):335-47.
  55. Gandoglia, I.; Ivaldi, F.; Carrega, P.; Armentani, E.; Ferlazzo, G.; Mancardi, G.; Kerlero de Rosbo, N.; Uccelli, A.; Laroni, A. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. Immunol Lett. 2017 Jan;181:109-115.
  56. Kimura, K.; Nakamura, M.; Sato, W.; Okamoto, T.; Araki, M.; Lin, Y.; Murata, M.; Takahashi, R.; Yamamura, T. Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 3;3(2):e210.
  57. Nizar, S.; Meyer, B.; Galustian, C.; Kumar, D.; Dalgleish, A. T regulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta. 2010 Aug;1806(1):7-17.
  58. Jacobs, JF.; Nierkens, S.; Figdor, CG.; de Vries, IJ.; Adema, GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012 Jan;13(1):e32-42.
  59. Ladányi, A.; Kiss, J.; Mohos, A.; Somlai, B.; Liszkay, G.; Gilde, K.; Fejös, Z.; Gaudi, I.; Dobos, J.; Tímár, J. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 2011; 60:1729-38; PMID:21779876.
  60. Erdag, G.; Schaefer, JT.; Smolkin, ME.; Deacon, DH.; Shea, SM.; Dengel, LT.; Patterson, JW.; Slingluff, CL. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72:1070-80.
  61. Garg, K.; Maurer, M.; Griss, J.; Brüggen, MC.; Wolf, IH.; Wagner, C.; Willi, N.; Mertz, KD.; Wagner, SN. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol 2016; 54:157-64.
  62. Hussein, MR.; Elsers, DA.; Fadel, SA.; Omar, AE. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol 2006; 59:316-24.
  63. Martinez-Rodriguez, M.; Thompson, AK.; Monteagudo, C. A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma. Histopathology 2014; 65:726-8.
  64. Chiaruttini, G.; Mele, S.; Opzoomer, J.; Crescioli, S.; Ilieva, KM.; Lacy, KE.; Karagiannis, SN. B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment, OncoImmunology 2017 6:4.
  65. Kok, LF.; Ferguson, AL.; Marshall, JE.; Tse, BCY.; Halliday, GM.; Byrne, SN. B Cell-Targeted Immunotherapy Limits Tumor Growth, Enhances Survival, and Prevents Lymph Node Metastasis of UV-Induced Keratinocyte Cancers in Mice. J Invest Dermatol. 2020 Jul;140(7):1459-1463.
  66. Byrne, SN.; Halliday, GM. B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J Invest Dermatol. 2005 Mar;124(3):570-8.
  67. Alatrash, G.; Albitar, M.; O’Brien, S.; Wang, X.; Manshouri, T.; Faderl, S.; Ferrajoli, A.; Burger, J.; Garcia-Manero, G.; Kantarjian, HM.; Lerner, S.; Keating, MJ.; Wierda, WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb;148(3):386-93.
  68. Albitar, M.; Do, KA.; Johnson, MM.; Giles, FJ.; Jilani, I.; O’Brien, S.; Cortes, J.; Thomas, D.; Rassenti, LZ.; Kipps, TJ.; Kantarjian, HM.; Keating, M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 1;101(5):999-1008.
  69. Wang, J.; Zhang, G.; Sui, Y.; Yang, Z.; Chu, Y.; Tang, H.; Guo, B.; Zhang, C.; Wu, C. CD52 Is a Prognostic Biomarker and Associated With Tumor Microenvironment in Breast Cancer. Front Genet. 2020 Nov 2;11:578002.
  70. de Vos-Hillebrand, L.; Fietz, S.; Hillebrand, P.; Kulcsár, Z.; Diop, MY.; Hollick, S.; Maas, AP.; Strieth, S.; Landsberg, J.; Dietrich, D. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma. Pigment Cell Melanoma Res. 2024 Mar;37(2):309-315.
Table 1. Skin malignancies reported in studies for each Monoclonal Antibody.
Table 1. Skin malignancies reported in studies for each Monoclonal Antibody.
MONOCLONAL ANTIBODY STUDY SKIN MALIGNANCIES
NATALIZUMAB AFFIRM (Polman et al., 2006) 1 metastatic melanoma
TOP (Butzkueven et al., 2020) 2 basal cell carcinoma,
2 melanoma in situ,
1 lentigo maligna,
1 choroidal melanoma
1 ocular melanoma
SONAR (Sabol et al., 2017) 137 melanoma (from FAERS)
7 melanoma (from peer-reviewed publications)
RADAR (Kelm et al., 2019) 205 melanoma (from FAERS)
78 melanoma (from EudraVigilance)
3 melanoma (from NMEDW)
Castela et al., 2011 no changes of 248 pigmented lesion
Pharaon et al., 2014 no changes of 775 melanocytic skin lesions
Alping et al., 2020 2 melanoma
TYGRIS (Foley et al., 2020) 10 basal cell carcinoma
13 melanoma
OCRELIZUMAB OPERA (Hauser et al., 2017) 1 melanoma
+in EP: 1 melanoma and 2 basal cell carcinoma
ORATORIO (Montalban et al., 2017) 3 basal-cell carcinoma
+ in EP: 1 squamous-cell carcinoma and
1 basal cell carcinoma
CASTING (Vermersch et al., 2022) 1 basal cell carcinoma
Smoot et al., 2021 4 basal cell carcinoma
1 melanoma
CONFIDENCE (Dirks et al., 2020) 3 melanoma, 2 basal cell carcinoma, 1 squamous cell carcinoma of the skin
OFATUMUMAB ASCLEPIOS (Hauser et al., 2020) 2 basal cell carcinoma
1 melanoma
ALEMTUZUMAB CARE-MS I - II (Cohen et al., 2012, Coles et al., 2012) 6 basal cell carcinoma
4 melanoma
CAMMS03409 and TOPAZ (Coles et al., 2008; Okai et al., 2019) 2 melanoma
* Legend: EP: open-label extension phase.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated